PCM
GSK icon

Poehling Capital Management’s GSK GSK Stock Holding History

Poehling Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-160
Closed -$8K – 175
2018
Q2 		$8K Sell
160
-862
-84% -$43.4K 0.01% 237
2018
Q1 		$50K Hold
1,022
– – 0.04% 144
2017
Q4 		$45K Buy
+1,022
New +$47.2K 0.04% 152

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Poehling Capital Management's GSK Position: Q3 2018 in Review

Poehling Capital Management sold out of GSK (GSK) in Q3 2018, closing a stake of 160 shares — an estimated $8K sold.

Poehling Capital Management first reported a position in GSK in Q4 2017 and held it in 3 quarters. The position peaked at $50K in Q1 2018. 787 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

  • Poehling Capital Management reported no remaining GSK position as of Q3 2018 after selling out during the quarter.
  • Poehling Capital Management sold 160 GSK shares in Q3 2018, an estimated $8K.
  • Poehling Capital Management first reported a position in GSK in Q4 2017 and held it in 3 quarters.
  • Poehling Capital Management's GSK position peaked at $50K in Q1 2018.
  • 787 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on Poehling Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.